GILD
Gilead Sciences Inc
NASDAQ: GILD · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$130.84
+1.55% today
Updated 2026-04-29
Market cap
$161.85B
P/E ratio
19.23
P/S ratio
5.50x
EPS (TTM)
$6.78
Dividend yield
2.36%
52W range
$93 – $156
Volume
6.1M
Gilead Sciences Inc (GILD) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
-20.5%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-100.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+2.6%
Last 4 reports
Positive reaction rate
75%
3 of 4 quarters
Largest single-day move
+8.3%
2025-08-07
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-04-23 | $0.00 | -100.0% | $132.90 | $130.40 | -1.9% |
| 2026-02-10 | $1.86 | +0.5% | $151.68 | $155.80 | +2.7% |
| 2025-10-30 | $2.47 | +14.9% | $118.50 | $119.79 | +1.1% |
| 2025-08-07 | $2.01 | +2.6% | $110.28 | $119.41 | +8.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $1.89 | $0.00 | -100.0% | — | — |
| 2025-12-31 | $1.85 | $1.86 | +0.5% | $7.92B | +4.7% |
| 2025-09-30 | $2.15 | $2.47 | +14.9% | $7.77B | +3.0% |
| 2025-06-30 | $1.96 | $2.01 | +2.6% | $7.08B | +1.8% |
| 2025-03-31 | $1.77 | $1.81 | +2.1% | $6.67B | -0.3% |
| 2024-12-31 | $1.70 | $1.90 | +11.7% | $7.57B | +6.4% |
| 2024-09-30 | $1.55 | $2.02 | +30.3% | $7.54B | +7.0% |
| 2024-06-30 | $1.60 | $2.01 | +25.6% | $6.95B | — |
| 2024-03-31 | $-1.49 | $-1.32 | +11.4% | $6.69B | — |
| 2023-12-31 | $1.76 | $1.72 | -2.3% | $7.11B | — |
| 2023-09-30 | $1.92 | $2.29 | +19.3% | $7.05B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $8.84 | $30.8B | +4.7% | 18 | high |
| 2027 (E) | $9.82 | $32.6B | +6.0% | 18 | high |
| 2028 (E) | $10.78 | $34.7B | +6.3% | 18 | medium |
| 2029 (E) | $11.89 | $37.1B | +7.0% | 18 | medium |
| 2030 (E) | $13.15 | $39.9B | +7.3% | 18 | medium |
Frequently asked questions
Has Gilead Sciences Inc beaten earnings estimates?
Gilead Sciences Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of -20.5% over the last 4 quarters.
How does GILD stock react to earnings?
GILD stock has moved an average of +2.6% in the trading day following earnings over its last 4 reports, with positive reactions in 75% of those quarters.
What is the expected EPS for GILD in 2026?
Analysts expect Gilead Sciences Inc to report EPS of $8.84 for fiscal year 2026, on revenue of $30.8B, based on estimates from 18 analysts.